A Randomized, First‐in‐Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1111
Abstract: Aberrant activation of the classical complement pathway is the common underlying pathophysiology of orphan diseases such as bullous pemphigoid, antibody‐mediated rejection of organ transplants, cold agglutinin disease, and warm autoimmune hemolytic anemia. Therapeutic options for… read more here.
Keywords: inhibition classical; sutimlimab humanized; complement pathway; classical complement ... See more keywords